Get the Stockscreener App
2.43
2.02%
-0.05
Acurx Pharmaceuticals Inc stock is currently priced at $2.43, with a 24-hour trading volume of 46,272.
It has seen a -2.02% decreased in the last 24 hours and a +16.27% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.43 pivot point. If it approaches the $2.37 support level, significant changes may occur.
Previous Close:
$2.48
Open:
$2.43
24h Volume:
46,272
Market Cap:
$38.50M
Revenue:
-
Net Income/Loss:
$-14.58M
P/E Ratio:
-2.1504
EPS:
-1.13
Net Cash Flow:
$-9.80M
1W Performance:
+1.25%
1M Performance:
+16.27%
6M Performance:
-27.68%
1Y Performance:
-12.90%
1D Range:
$2.3551
$2.48
52W Range:
$1.17
$8.82
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917 533 1469
Address
259 Liberty Avenue, Staten Island
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
Acurx Pharmaceuticals (NASDAQ:ACXP) Trading Up 6.3% - Defense World
Defense World
12 Health Care Stocks Moving In Tuesday's After-Market Session - Acurx Pharmaceuticals (NASDAQ:ACXP), Bio - Benzinga
Benzinga
Q2 2024 Earnings Forecast for Cabaletta Bio, Inc. Issued By HC Wainwright (NASDAQ:CABA) - Defense World
Defense World
HC Wainwright Reiterates Buy Rating for Acurx Pharmaceuticals (NASDAQ:ACXP) - Defense World
Defense World
Acurx reports results from meeting with FDA regarding ibezapolstat - TipRanks
TipRanks
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Acurx Pharmaceuticals Inc (ACXP) Net Income 2024
ACXP net income (TTM) was -$14.58 million for the quarter ending December 31, 2023, a -20.55% decrease year-over-year.
Acurx Pharmaceuticals Inc (ACXP) Cash Flow 2024
ACXP recorded a free cash flow (TTM) of -$9.80 million for the quarter ending December 31, 2023, a -29.95% decrease year-over-year.
Acurx Pharmaceuticals Inc (ACXP) Earnings per Share 2024
ACXP earnings per share (TTM) was -$1.15 for the quarter ending December 31, 2023, a -2.68% decline year-over-year.
About Acurx Pharmaceuticals Inc
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York.
0.87%
0.21%
Cap:
|
Volume (24h):